SCHEMBL4480897

SCHEMBL4480897

COc1ccc(-c2nsc(N3CCNCC3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.54
HTR3A P46098 3/20 0.51
ADRB1 P08588 2/20 0.51
HTR3E A5X5Y0 2/20 0.51
HTR3B O95264 2/20 0.51
HTR3D Q70Z44 2/20 0.51
HTR3C Q8WXA8 2/20 0.51
SIGMAR1 Q99720 1/20 0.51
HTR1A P08908 4/20 0.49
HTR7 P34969 3/20 0.49
HTR2B P41595 2/20 0.49
HTR1B P28222 2/20 0.49
HTR6 P50406 1/20 0.49
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
UBE2N P61088 1/20 0.47
TLR9 Q9NR96 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14486537 0.85 CYP1A2 (0.57) FAAHHTR3AADRB1HTR1AHTR7
SCHEMBL4483992 0.85 FAAH (0.51) FAAHHTR3AADRB1HTR1AHTR7
SCHEMBL4482673 0.82 FAAH (0.51) FAAHHTR3AADRB1HTR3EHTR3B
SCHEMBL532234 0.81 FAAH (0.55) FAAHNPC1RAB9A
SCHEMBL14488223 0.80 HRH4 (0.48) FAAHNPC1RAB9A
SCHEMBL2011584 0.79 HTR3A (0.49) HTR3AADRB1HTR3EHTR3BHTR3D
SCHEMBL14486458 0.78 SIGMAR1 (0.58) FAAHSIGMAR1KMT2ARAB9A
SCHEMBL12244737 0.78 HRH3 (0.65) FAAHALDH1A1
SCHEMBL14488329 0.77 CHEK1 (0.46) FAAHHTR1AHTR7HTR2BHTR1B
SCHEMBL2007027 0.77 FAAH (0.51) FAAHHTR3AHTR1AHTR7HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541359-B2 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-02 US disclosed
US-7541359-B2 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-02 US disclosed
US-7541359-B2 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-02 US disclosed
WO-2007005510-A1 N-HETEROARYLPIPERAZINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-11 WO disclosed
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase APODACA RICHARD 2007-01-04 US disclosed
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase APODACA RICHARD 2007-01-04 US disclosed
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase APODACA RICHARD 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase FAAH, FAAH2, CNR2 FAAH 1/4885HTR3A 302/4885ADRB1 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.